Bioasis sells royalty rights to four drugs for $1.2M
A California company has paid
Bioasis Technologies$1.2 million for a royalty interest in four rare disease drugs the Guilford biotech is developing with an Italian health care group.
The deal announced Tuesday centers on enzymes Bioasis is investigating as potential treatments for four undisclosed lysosomal storage disorders.
more